The Motley Fool
20 Jul 2026, 23:24 UTC · 10h ago
What This MannKind Filing Reveals About Three Years of Underperformance
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
20 Jul 2026, 23:24 UTC · 10h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
United Therapeutics' product Tresmi is positioned as a 'category killer' competitor to Tyvaso DPI, the inhaler MannKind collects royalties on. — Direct competition from a 'category killer' threatens a significant revenue stream, as Tyvaso royalties contributed substantially to recent quarterly revenue.
-0.70MannKind EVP Sanjay R. Singh forfeited 14,450 shares because the company failed to meet its 2023 compensation performance targets. — Forfeiture of shares by an executive due to missed targets serves as a negative signal regarding internal performance and growth trajectory.
-0.40MannKind EVP Sanjay R. Singh sold 46,795 shares of common stock on July 15, 2026. — Insider selling is generally viewed with caution, though the impact is mitigated here by the fact that a large portion was for tax obligations.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Executive forfeited shares due to performance shortfalls and faces a 'category killer' competitor product threatening royalties.
The company introduced a product described as a 'category killer' that negatively impacts a competitor's market position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
8h ago
